Program Announcement for the Defense Health Agency

Bone Marrow Failure Research Program

Resource Development Award

Funding Opportunity Number: HT942526BMFRPRDA

Pre-Application Due: October 7, 2026

Application Due: November 4, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click ⓘ to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource for the BMF research and clinical communities and is expected to facilitate key discoveries that advance the understanding of BMF diseases.

Distinctive Features: The application must include a robust **Data Resource Sharing Plan** that describes the means and timeline by which the fully developed resource will be made available to the scientific and clinical community.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $1.25M to fund approximately one Resource Development Award application with total cost caps of $1.25M per award. The maximum period of performance is 2 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), October 7, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 4, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 12, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526BMFRPRDA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators at all career levels affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status.

An investigator may be named as a PI on a maximum of two applications to this program announcement. If an investigator is named as a PI on more than two Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) applications, only the first two applications received will be accepted; additional applications will be administratively withdrawn.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the BMFRP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the BMFRP in FY08 to provide support for research that has high potential impact and exceptional scientific merit in bone marrow failure. Appropriations for the BMFRP from FY08 through FY24 totaled $71.55 million (M). The FY26 appropriation is $7.5M.

The vision of the BMFRP is to understand and cure bone marrow failure (BMF) diseases. The program mission challenges the scientific community to design innovative research of inherited and acquired BMF diseases to improve understanding of the pathobiology and advance prevention and treatment. Through these efforts, the BMFRP seeks to improve the health of affected Service Members, Veterans, and the general public, with the ultimate goal of cure.

BMFRP Objective

The BMFRP objective is to fund research in the areas of inherited or acquired BMF. Studies focusing on BMF syndromes and their progression to other malignancies, such as leukemia, are eligible for funding. ***However, the BMFRP will not consider research with a primary focus on myeloproliferative neoplasms, leukemia, or other malignancies.*** *Applications proposing stem cell biology studies and translational projects, including bone marrow transplantation studies and cellular therapies, should clearly relate to BMF diseases.*

*Projects related to **Graft Versus Host Disease (GVHD)** must explain how the issues the proposed research is investigating **are specifically relevant to BMF**, but not other stem cell transplant patients. Applications should describe the experimental design **for using BMF models** to directly test the proposed hypotheses. The BMFRP will not consider GVHD studies in the context of other hematological disorders.*

The BMFRP encourages research that improves the understanding and treatment of BMF diseases and conditions. To assist with the application review process, applicants **must** specify the type(s) of BMF disease or condition that will be the primary focus of the investigation. The following is a non-exhaustive list of diseases and conditions relevant to the objective of the BMFRP:

- Aplastic Anemia
- Diamond-Blackfan Anemia
- Dyskeratosis Congenita/Telomere Biology Disorders
- Fanconi Anemia
- GATA2 Deficiency
- Induced BMF: Radiation/Chemical
- Myelodysplastic Syndromes
- Paroxysmal Nocturnal Hemoglobinuria
- Pearson Syndrome
- SAMD9/SAMD9L Germline Mutations
- Severe Congenital Neutropenia
- Shwachman-Diamond Syndrome
- VEXAS Syndrome
- Adenosine Deaminase 2 Deficiency

If the proposed research project focuses on a disease that is not listed, the application should clearly identify the disease or condition that is central to the study and provide justification

demonstrating that the project aligns with the objective of the BMFRP. If the proposed research project is not specific to one disease or condition and addresses multiple BMF diseases or conditions, the application should clearly articulate the specific patient communities that will benefit from the study.

3.1. Award History

The BMFRP RDA mechanism was previously offered in FY11, when four applications were received and one was recommended for funding.

3.2. Intent of the Resource Development Award

The BMFRP RDA supports the development of a multiomic atlas generated from well-annotated human BMF samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource to be shared with the BMF research and clinical communities and is expected to facilitate further key discoveries that advance the understanding of BMF diseases.

This funding opportunity invites proposals that will utilize previously stored viable human marrow samples, and may include newly collected specimens, to generate comprehensive data resources, such as genomic, transcriptomic, proteomic, metabolomic, and epigenomic data. Proposals must include single-cell omic analyses of human marrow specimens as a foundational component. Additional data types, such as serum metabolomic or other omic modalities, may be incorporated only if they are accompanied by single-cell transcriptomic data from the same specimens. Investigators are also encouraged to provide matched induced pluripotent stem cell (iPSC) lines that correspond to the single-cell omic captures of the original material, where available. Non-biospecimen data (such as patient reported outcomes) may be integrated to enrich the biospecimen data. The goal is to support the collection, processing, storage, and analysis of these biospecimens to create robust datasets for one or more BMF diseases, thereby advancing the understanding of disease mechanisms and enabling future research.

Award funds may be used for activities such as the collection and processing of biospecimens, quality control, and the generation of multiomic data from both new and existing samples. While the primary focus is on the creation of multiomic datasets, applicants are encouraged to propose additional relevant omic analyses of marrow cell data that are clearly justified and aligned with the needs of the BMF research community.

To maximize the impact and diversity of the resulting resource, multi-institutional collaborations are strongly encouraged, particularly those that broaden the range and depth of available patient samples. All supported projects are expected to maintain high standards of data quality, annotation, and ethical compliance, contributing generated datasets to an open-access, durable resource for the BMF research community.

The FY26 BMFRP RDA mechanism supports the development of a multiomic atlas of human BMF. Clinical trials or inclusion of animal data are NOT allowed under this award mechanism.

3.2.1. Focus Area for the RDA

Applications must address the following FY26 BMFRP focus area:

- Develop durable resources for the BMF research community

3.2.2. Key Elements for the RDA

The following are significant features of this award mechanism:

- **Multiomic Atlas Development:** The key outcome of this funding opportunity will be the development of a comprehensive multiomic atlas from well-annotated bone marrow samples, aiming to establish a durable, open-access resource for the BMF research community. Public access may be through existing, well-annotated repositories or through the development of a new resource. Applications describing development of a new open-access resource must demonstrate the ability to host large datasets and perform data curation.
- **Data Resource Sharing:** This funding opportunity requires that all resulting data developed under this award mechanism be freely accessible to the BMF research, clinical and patient communities and made available to the general public.
- **Impact:** Proposed multiomic atlas projects should result in a high-quality, well-annotated dataset that captures the complexity of BMF syndromes and provides a basis for future studies that interrogate the data to better understand BMF disease mechanisms and potential treatment pathways.
- **Preliminary Data:** Applications must include preliminary and/or published data that are relevant to the mission of the BMFRP and support the proposed multiomic atlas project. Any unpublished preliminary data provided should originate from the laboratory of the PI or a member(s) of the research team.
- **Personnel:** The application should demonstrate expertise in BMF diseases and multiomic research, laboratory analyses, and data management through the combined background of the PI, project team, and any collaborations.
- **Multidisciplinary Collaborations:** Applicants are encouraged to form multidisciplinary teams of investigators who bring specific skills that contribute to the successful completion of the project. Such contributions can include both intellectual input and research resources (e.g., laboratory analyses, data annotation, and subsequent data recall, as well as biospecimens and/or access to patients and populations).
- **Sustainment:** The sustainability of the data resource is an essential component of the RDA, and plans should include the feasibility of future data expansion.

3.2.3. Other Important Considerations for the RDA

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **2** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$1.25M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **2** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for two investigators to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 BMFRP Resource Development Award.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.
- Animal studies costs.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following component.

Letter of Intent (LOI) (one-page limit): Provide a brief description of the proposed multiomic atlas resource, specifying the BMF patient population(s) and the biospecimens to be used (including the required bone marrow samples) from which the data will be derived.

LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review. ***An invitation to submit a full application is NOT provided after LOI submission. Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.***

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative 12-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  - **BMFRP Objective:** Describe how the proposed project adheres to the intent of the FY26 BMFRP Objective. Identify the relevant BMF disease(s) or condition(s), and explain how the proposed work addresses the FY26 BMFRP Focus Area.

- **Background:** Present the ideas and reasoning to support the proposed project. Describe the multiomic data atlas to be developed and provide a rationale that supports the need for this resource. Clearly demonstrate a comprehensive understanding of critical barriers and gaps in BMF research that will be addressed with the resource. Cite relevant literature. ***The inclusion of preliminary data is required.*** Applicants must provide preliminary data that clearly demonstrate the unmet need in BMF research that their project aims to address. Data that exhibit proficiency with advanced single-cell omic technologies and/or the accompanying data collection scheme must be included. Proof-of-concept data from pilot, small-scale, multiomic analyses may be included to demonstrate the feasibility of developing the atlas.
- **Specific Aims:** Concisely explain the project's specific aims. The aims should align with the associated tasks described in the Statement of Work (Attachment 5). If this research project is part of a larger study, present only the tasks that this award would fund.
- **Project Design:**
  - Describe the study design, methods, and analyses, including relevant controls, in sufficient detail to allow assessment of their appropriateness and feasibility. Provide a detailed description of the specific omic studies to be performed and the types of data to be collected. Specify whether each patient biospecimen is sufficient in size to support all planned omic analyses, or if separate biospecimens will be required for different studies. Additionally, indicate whether generating the multiomic dataset will deplete or destroy the available biospecimens.
  - Briefly describe how the data will be collected, analyzed, annotated, organized, and stored in a manner that is consistent with the study objectives. More details will be required in the Data Management Plan (Attachment 7).
  - Briefly describe how the multiomic atlas resource will be shared with the BMF research, clinical and patient communities, as well as the general public, and outline the strategy for maintaining it as a long-term durable resource. Additional details will be required in the Data Resource Sharing Plan (Attachment 8) and the Sustainment Plan (Attachment 9).
  - Identify potential problem areas and present alternative methods and approaches to address them.
- **Human Biospecimens:**
  - Identify the patient biospecimens available to the study, specifying disease types, biospecimen types (e.g., bone marrow, biopsy, iPSCs), the total number of biospecimens, the number of serial biospecimens, etc.
  - Identify any control biospecimens to be included and describe the nature of the control (e.g., healthy control, family member control, patient pre-treatment control).
  - Identify the source(s) of the biospecimens, how they are stored, who owns/controls them, how the study team will have access to them, and how they will be transported, if applicable. If the biospecimens are not owned/controlled by the PI, a letter confirming access must be uploaded under Supporting Documentation (Attachment 2).

- **Military/VA Populations:** If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed study. Also include a plan for obtaining any required data sharing agreements, memorandums of understanding, or other agreements necessary to access and publish the data. Refer to the GAI, Appendix 4, for additional considerations.
- **Statistical Plan:** Clearly describe the statistical plan and provide a rationale for the chosen statistical methodology, explaining its appropriateness for the proposed study. Given the importance of the number of patients sampled in evaluating the impact of the atlas, provide a sample-size estimate and the method by which it was derived, including a power analysis calculation, as applicable. Include any plans for blinding and randomization.
- **Sex as a Biological Variable (SABV):** Describe how sex as a biological variable will be considered, including the collection of data disaggregated by sex and a brief description of a sufficiently powered statistical analysis for sex differences. The SABV strategy should be provided as part of the application's Supporting Documentation (Attachment 2).
- **Women and Minorities in Research:** For all applications proposing clinical research, including prospective specimen collection and/or the use of existing clinical samples for resource development, describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, race, and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. ***This award cannot be used to conduct clinical trials.*** Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race, and ethnicity should be provided as part of the application's Supporting Documentation (Attachment 2).

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

  There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

  References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

  List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

  Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support (two-page limit per letter): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the U.S. Department of Veterans Affairs (VA) Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual and/or organization demonstrating that the PI has the support and resources necessary for the proposed work. If an investigator at an intramural DOW organization is named as a collaborator on a full application submitted through an extramural organization, the application must include a letter from the collaborator's Commander or Commanding Officer at the intramural DOW organization authorizing the collaborator's involvement.

Letters of Access (if applicable): If access to patients, patient samples, patient datasets, or other resources is necessary to conduct the study, and the PI or key personnel on this application does not own the resource, provide a letter of support signed by the appropriate authorizing individual confirming access to the resource.

Sex as a Biological Variable Strategy (two-page limit is recommended): Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Inclusion Enrollment Report *(only required if clinical research is proposed)*: Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "Public Health Service (PHS) Inclusion Enrollment Report", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.

Use of DOW Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOW resources or databases.

Use of VA Resources (if applicable): Provide a letter of support signed by the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research. If the VA-affiliated non-profit corporation is not identified as the applicant organization for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Intellectual Property: Information can be found in the 2 CFR 200.315, "Intangible Property."

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the scientific rationale behind developing the proposed multiomic atlas resource, and its feasibility given the number, types, and quality of biospecimens available, including appropriate controls.

Objective: State the overall objective(s) of the study.

BMFRP RDA Focus Area: State whether the proposed project addresses the FY26 BMFRP Focus Area.

Specific Aims: State the specific aims of the study.

- **Study Design:** Briefly describe the study design, including the appropriate controls and the multiomic facilities.
- **Impact:** Summarize how the proposed multiomic atlas resource will benefit the BMF research, clinical and patient communities, as well as the general public, in the short- and long-term. Explain how this resource will advance the mission of the BMFRP to understand and cure BMF diseases. Identify the specific BMF disease(s) that will be particularly impacted by the research.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- State how the proposed project addresses the FY26 BMFRP Focus Area.
- Summarize the objectives and rationale for the proposed study.
  - Describe the ultimate applicability of the resource
  - What bone marrow disease/syndrome is the study seeking to address and how will it help?
  - Summarize how the proposed resource will lead to new avenues of discovery or development.

- If the project is too basic for immediate clinical applicability, then describe the interim outcomes.
- What are the potential applications, benefits, and risks of the anticipated outcomes?
- What are the likely contributions of the proposed project to advancing the field of BMF research and/or patient care among those with BMF diseases/syndromes?

- **Attachment 5: Statement of Work (five-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

  For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Impact Statement (one-page limit): Upload as "Impact.pdf".** ***The impact statement should be written with a broad audience in mind, including readers without a background in science or medicine.***
  - Describe how the proposed multiomic atlas resource addresses the FY26 BMFRP Focus Area, and how it will advance the mission of the BMFRP to understand and cure BMF diseases.
  - Describe the short-term impact: Detail how the proposed multiomic atlas resource will benefit the BMF research, clinical and patient communities, as well as the general public in the near-term.
  - Describe the long-term impact: Explain how the proposed multiomic atlas resource will drive the BMF field forward and support new avenues for research or clinical care.
  - If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

- **Attachment 7: Data Management Plan (no page limit): Upload as "DataPlan.pdf".** Provide a data management plan that includes:
  - The types and formats of data to be collected and generated, including but not limited to genomic, transcriptomic, proteomic data, as well as clinical and demographic data, as available.
  - The protocols for data acquisition, including the time and location of data acquisition where scientifically pertinent.
  - The methods for data collection, including standard operating procedures for sample handling, data generation, and metadata annotation practices.
  - A description of how the data will be processed, including the file formats and naming conventions that will be used. Include the approach for processing and aligning FASTQ files. Specify which reference clusters will be used, if de novo clustering is planned, and provide a justification for this choice.
  - The quality assurance and quality control measures during collection, analysis, and processing, including data validation procedures.
  - A description of the dataset origin when existing data resources are used, including the standards to be used for data and metadata formats and content.
  - The data security measures appropriate for protecting data confidentiality, integrity, and availability.

- The long-term data preservation strategies, including the appropriate timeframe for preservation, archiving in established BMF repositories (if applicable), backup procedures, and disaster recovery plans.
- The personnel responsible for data management, sharing, and oversight.

An additional Data Management Plan that conforms to the format established in Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested only after a recommendation for funding is made.

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan.

- **Attachment 8: Data Resource Sharing Plan (no page limit): Upload as "DataSharing.pdf".** Describe how data resources generated during the performance of the project will be shared with the research, clinical and patient communities. If applicable, detail how the cell barcodes will be linked to cluster annotations, and explain how the research community will be able to access and utilize these data. Describe whether the proposed plan for resource sharing includes existing publicly available BMF data repositories/platforms, or whether a new repository/platform will be created. Include strategies for making raw data and multiomic atlas(es) developed as part of the proposed project widely available to the research, clinical and patient communities. ***Provide a milestone plan for data resource sharing,*** including the timeline and methods by which the research, clinical and patient communities will be informed of the availability and accessibility of the resource. Explain organizational and technical capabilities that support data resource sharing in a timely manner. The government reserves the right to identify repositories for submission of data for archive. Any costs associated with submission will be addressed during award negotiations. If there are limitations associated with a pre-existing agreement for the original data or research resources that preclude subsequent sharing, the applicant should explain this.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

  Do not submit a copy of the NIH Data Management and Sharing Plan.

- **Attachment 9: Sustainment Plan (two-page limit): Upload as "Sustainment.pdf".** Outline potential resources and plans for long-term sustained operations and improvements beyond the award period:
  - Identify the individual(s) or organization responsible for maintaining the resource, including ensuring data security, integrity, and accessibility.
  - Describe the methods by which questions, problems, or requests from the research, clinical and patient communities related to the resource will be received and addressed, including the communication channels (e.g., email, web portal, helpdesk).
  - If maintenance will require financial support, estimate the annual maintenance cost and describe how it will be supported.
  - Describe processes, partnerships, or agreements to secure ongoing support for sustainment of the data resource sharing effort.
  - Provide plans for sustainable operations, including continued accrual and data curation for resource expansion to advance BMF research.

- **Attachment 10: Project Team Statement (one-page limit): Upload as "Team.pdf".** Describe how the team collectively possesses the necessary expertise in BMF disease, multiomic research, data management/security and resource sharing/dissemination. Explain how the team's expertise will support the successful development, management, and sustainment of the proposed resource. Highlight any collaborative arrangements or partnerships that enhance the team's capabilities. Identify key team members, their roles, and relevant qualifications or experience. Clearly state whether key personnel are not receiving salary from the award. If applicable, provide assurances/letters of commitment that the unpaid personnel will contribute the required level of effort to complete the project. Describe the PI's record of accomplishment and their ability to lead the team to accomplish the proposed project.
- **Attachment 11: Justification Statement (one-page limit): Upload as "Justification.pdf".** Describe how the quantity and type of biospecimens available and/or to be acquired are sufficient to support the proposed omic studies, and how the amount and type of data generated will be sufficient to support future research investigations and downstream interrogation. The samples may span different types of BMF diseases but must address the objective of the project.
- **Attachment 12: Regulatory Statement (for applications recruiting human subjects; two-page limit): Upload as "RegState.pdf".** Outline the processes that will govern legal, ethical, and human subject issues, as well as the use of human biospecimens in the proposed research. Describe the appropriate plans for the coordination of regulatory submissions and approvals at participating sites. Discuss the plans for obtaining patient informed consent.

  If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Attachment 13: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 14: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI:

Grants.gov eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526BMFRPRDA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire

pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 BMFRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 BMFRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Project Design**
  - How well the scientific rationale supports the FY26 BMFRP Objective and the need for the proposed multiomic data atlas to be developed.
  - How well the study design, methods, and analyses are appropriate and sufficient for developing the proposed multiomic data atlas.
  - To what extent the biospecimens to be used in this project, including patient samples and controls, are identified, available, accessible, appropriate, and sufficient to yield well-annotated data for the planned multiomic data atlas.
  - Whether the number and types of human samples available and/or to be acquired are clearly described, appropriate, and sufficient to support any proposed omic studies.

- If the samples span different types of BMF diseases, how well the rationale for their inclusion is justified and scientifically sound.
- To what extent the amount and type of data generated will be robust and comprehensive enough to inform future research investigations.
- The extent to which the plans for data collection, validation, annotation, organization, quality control, and storage are appropriate and sufficient to meet the study objectives.
- The extent to which the plans for data security measures, including data confidentiality, integrity, availability, preservation, and recovery, are appropriate and sufficient.
- How well the application acknowledges potential problems and addresses alternative approaches and potential pitfalls.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.

- **Impact**
  - How well the proposed multiomic resource addresses the FY26 BMFRP Focus Area and will advance the mission of the BMFRP to understand and cure BMF diseases.
  - How well the proposed multiomic data atlas will benefit the BMF research, clinical and patient communities, and the general public in the near-term.
  - To what degree the anticipated long-term gains from the proposed project will drive the BMF field forward and support new avenues for research or clinical care.
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Data Resource Sharing Plan**
  - The extent to which the plan for data resource sharing is described, feasible, and appropriate.
  - The extent to which the proposed plan for research sharing includes existing publicly available BMF data repositories/platforms or the creation of a new repository/platform.
  - To what extent the strategies for making raw data and multiomic atlas(es) widely available, including the proposed timeline, communication methods, and milestone plan for notifying the research, clinical and patient communities about the availability and accessibility of the resource, are adequate.
  - To what extent the plan describes organizational and technical capabilities sufficient to share project data in a timely manner.
- **Sustainment Plan**
  - The extent to which the individual(s) or organization responsible for maintaining the resource, including ensuring data security, integrity, and accessibility, beyond the award period, are identified and appropriate.
  - To what extent the methods by which questions, problems, or requests from the research, clinical and patient communities related to the resource will be received and addressed, including the communication channels (e.g., email, web portal, helpdesk) are sufficient.

- If maintenance of the resources requires financial support, how well the annual maintenance cost is estimated and the means of support described.
- To what extent the application demonstrates commitment to continue the effort following the award period through processes, partnerships, or agreements.
- To what extent the plan for long-term sustained operations is feasible, including the strategies for continual accrual and curation of data that will contribute to advancing BMF research.

- **Regulatory Process (if applicable)**
  - How well the application outlines a process that will govern legal, ethical, and human subject issues and the use of human biospecimens in research.
  - The extent to which the plans for the coordination of regulatory submissions and approvals at participating sites are appropriate and sufficient.
  - To what extent the plan for obtaining patient informed consent is sufficiently developed.
  - The extent to which the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
- **Personnel**
  - How appropriate the levels of effort are for successful conduct of the proposed work.
  - The extent to which the qualifications, roles, and experience of team members are described and appropriate for the project's scope.
  - To what extent the project team collectively possess the necessary expertise in BMF disease, multiomic research, data management and security, and resource sharing.
  - How well the team's expertise is leveraged to support the successful development, management, and sustainment of the proposed resource.
  - To what extent the PI's record of accomplishment demonstrates the ability to lead the team and achieve the project's objectives.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - If applicable, the extent to which the intellectual and material property plan is appropriate.

- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 BMFRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio composition
  - Relative impact
  - Data resource sharing and sustainment plans

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***CDMRP will NOT provide an invitation to submit a full application after pre-application submission.*** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the BMFRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports, as well as a final technical progress report, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting (required for research proposing clinical research): Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- Pre-application was not submitted.
- Project Narrative is missing.
- Budget is missing.
- Data Resource Sharing Plan is missing.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 BMFRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same project is submitted to different funding opportunities within the same program and fiscal year.
- If an investigator is named as a PI on more than two BMFRP RDA applications, only the first two applications received will be accepted; additional applications will be administratively withdrawn.
- The PI does not meet the eligibility criteria.
- The application does not address the FY26 BMFRP Focus Area.
- The proposed project includes animal data/research.
- Clinical trial is proposed.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	☐
Data Management Plan – Attachment 7, upload as "DataPlan.pdf"	☐
Data Resource Sharing Plan – Attachment 8, upload as "DataSharing.pdf"	☐
Sustainment Plan – Attachment 9, upload as "Sustainment.pdf"	☐
Project Team Statement – Attachment 10, upload as "Team.pdf"	☐
Justification Statement – Attachment 11, upload as "Justification.pdf"	☐
Regulatory Statement ***(if applicable)*** **– Attachment 12, upload as "RegState.pdf"**	☐
Representations ***(Grants.gov submissions only)*** **– Attachment 13, upload as "RequiredReps.pdf"**	☐
Suggested Intragovernmental/Intramural Budget Form ***(if applicable)*** **– Attachment 14, upload as "IGBudget.pdf"**	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) ***(if applicable)***	☐
Additional Application Components	
Confidential Letters of Recommendation	☐

Appendix 2. Acronym List

ACURO	Animal Care and Use Review Office
BMF	Bone Marrow Failure
BMFRP	Bone Marrow Failure Research Program
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions.
GVHD	Graft Versus Host Disease
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RDA	Resource Development Award
RPPR	Research Performance Progress Report
SABV	Sex as a Biological Variable
SAM	System for Award Management

SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs